Skip to NavigationSkip to content

Top Ten most popular articles on this week

Published on 24/05/19 at 10:24am

On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week's biggest stories in the pharmaceutical industry. From new positive data for Janssen's esketamine depression treatment and the news that MSD has agreed to buy Peloton Therapeutics for $2.1 billion, to pushes from Alexandria Ocasio-Cortez to grill Gilead's CEO on why its HIV prevention drug is more than 200 times more expensive in US than elsewhere, check out the 10 most popular stories on the website this week.

10. New Phase 3 data backs up the efficacy of esketamine in treatment-resistant depression

New research has been published on the efficacy of esketamine in the treatment of depression, following its approval from the FDA in the US in combination with oral antidepressants earlier this year.

9. The global rise in antibiotic resistance threatens infection prevention and cure

Dr Bill Love, Founder and Chief Scientific Officer of Destiny Pharma, discusses the rise of antimicrobial resistance (AMR), the antibiotic stewardship required to offset this global threat, and the additional incentivisation initiatives needed to promote innovation, as well as the role of preventative antimicrobial treatments as an important element of this global fight against AMR.

8. Takeda's Entyvio beats Humira for remission in ulcerative colitis, exploratory data show

Takeda has unveiled exploratory data on its gut-selective biologic drug Entyvio (vedolizumab) at the 2019 Digestive Disease Week, demonstrating its superiority over AbbVie’s best-selling anti-tumour necrosis factor-alpha (anti-TNFα) therapy Humira (adalimumab) in achieving remission in moderately to severely active ulcerative colitis (UC).

7. Amgen agrees to buy Nuevolution for $167 million

California biotech Amgen has agreed to buy Danish biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million).

6. MSD buys Peloton Therapeutics in deal worth $2.1 billion

US firm MSD will pay Texas-based biotech Peloton Therapeutics $1 billion upfront and a further $1.15 billion based on the achievement of regulatory and sales milestones.

5. Gilead CEO Daniel O'Day challenged over patents on PrEP drug Truvada

US Representative Alexandria Ocasio-Cortez tore into Gilead CEO Daniel O’Day on Thursday, over the firm’s nearly $2,000 price tag on PrEP drug, Truvada, in the United States. Sold at a list price of $1,780 in the US, the drug costs just $8 in Australia.

4. Drugmakers colluded to drive up price of anti-nausea drug by 700%

Four pharmaceutical firms have been accused of illegally colluding to restrict the supply of anti-nausea medication Prochlorperazine after the price of the drug increased by 700%.

3. Insider Interview: Paving paths in prostate cancer

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses Janssen’s vision in Oncology and how the company is building on its heritage in prostate cancer to deliver transformational outcomes for patient.

2. Sandoz is first multinational to secure generic approval under new Chinese guidelines

Sandoz has revealed that its generic statin rosuvastatin, known in its branded incarnation as Crestor, has been given approval in China from the country’s National Medical Products Administration (NMPA). The therapy was indicated for the reduction of heart disease risk and prevention of stroke and heart attack.

1. J&J to invest €100 million into Limerick manufacturing facilities creating 100 new jobs

Healthcare conglomerate Johnson & Johnson has said it will be investing €100 million into the expansion of its Vision Care manufacturing facilities in Limerick. The expansion is expected to see the creation of 100 new jobs.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches